EPOPROSTENOL
( DrugBank: Epoprostenol / KEGG DRUG: Epoprostenol )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 23 |
86. Pulmonary arterial hypertension
Clinical trials : 1,205 / Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193
Showing 1 to 10 of 23 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-142722 | 01/1/201520150101 | 27/11/201420141127 | ACT-385781A extension study for PAH pediatric patients | Open-label, long-term, efficacy, safety, and tolerability extension study using ACT-385781A in the treatment of Japanese children with pulmonary arterial hypertension who completed the AC-066A308 study. Open-label, long-term, efficacy, safety, and tolerability extension study using ACT-385781A in the t ... | Pulmonary arterial hypertension (PAH) | Intervention name : ACT-385781A INN of the intervention : epoprostenol Dosage And administration of the intervention : continuous intravenous infusion Intervention name : ACT-385781A INN of the intervention : epoprostenol Dosage And administration of th ... | Actelion Pharmaceuticals Japan Ltd. | NULL | 14 | BOTH | 3 | Phase 3 | NULL | ||
| 2 | JPRN-JapicCTI-142721 | 01/9/201420140901 | 27/11/201420141127 | ACT-385781A for PAH pediatric patients | Prospectiove, single-arm, Open-label, multi-center study to assess the efficacy, safety, and tolerability of ACT-385781A in Japanese children with pulmonary arterial hypertension. Prospectiove, single-arm, Open-label, multi-center study to assess the efficacy, safety, and tolerab ... | Pulmonary arterial hypertension (PAH) | Intervention name : ACT-385781A INN of the intervention : epoprostenol Dosage And administration of the intervention : continuous intravenous infusion Control intervention name : null Intervention name : ACT-385781A INN of the intervention : epoprostenol Dosage And administration of th ... | Actelion Pharmaceuticals Japan Ltd. | NULL | 14 | BOTH | 3 | Phase 3 | NULL | ||
| 3 | JPRN-JapicCTI-132142 | 01/4/201320130401 | 03/06/201320130603 | ACT-385781A PAH Post-marketing study | A Post-marketing, Open-label-study ACT-385781A in patients with pulmonary arterial hypertension | Pulmonary arterial hypertension (PAH) | Intervention name : ACT-385781A INN of the intervention : Epoprostenol Dosage And administration of the intervention : A commercially available epoprostenol sodium preparation will be switched to the study drug at the same dose Intervention name : ACT-385781A INN of the intervention : Epoprostenol Dosage And administration of th ... | Actelion Pharmaceuticals Japan Ltd. | NULL | 20 | BOTH | 5 | Phase 4 | NULL | ||
| 4 | EUCTR2010-018320-10-ES (EUCTR) | 26/12/201120111226 | 21/11/201120111121 | An extension of study AC-066A301 to investigate safety and tolerability of the study medication (epoprostenol for injection) An extension of study AC-066A301 to investigate safety and tolerability of the study medication (epo ... | An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A in patients with pulmonary arterial hypertension (PAH)Extension del estudio AC-066A301, abierta, para investigar la seguridad y la tolerabilidad de ACT-385781A en pacientes con Hipertension Arterial Pulmonar (HAP) - EPITOME-2 Extension An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A ... | Hipertension Arterial Pulmonar MedDRA version: 14.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Hipertension Arterial Pulmonar MedDRA version: 14.0;Level: PT;Classification code 10064911;Term: Pul ... | Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-385781A INN or Proposed INN: EPOPROSTENOL SODIUM Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-385781A INN or Proposed INN: EPOPROSTENOL SODIUM Trade Name: Epoprostenolfor injection Product Name: Epoprostenolfor injection Product Code: ACT-385781 ... | ACTELION Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | France;Canada;Belgium;Spain;Netherlands;Italy | |||
| 5 | EUCTR2011-002943-92-NL (EUCTR) | 07/11/201120111107 | 22/08/201120110822 | Study of a new thermostable formulation of Flolan™ to treat Pulmonary Arterial Hypertension (PAH) | A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN™ in Subjects with Pulmonary Arterial Hypertension (PAH) A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation ... | pulmonary arterial hypertension (PAH) MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 14.1;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;Classification code 10065152;Term: Familial pulmonary arterial hypertension;Classification code 10065151;Term: Idiopathic pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] pulmonary arterial hypertension (PAH) MedDRA version: 14.1;Level: PT;Classification code 10064911;Te ... | Trade Name: FLOLAN™ and Glycine Diluent Product Name: FLOLAN™ and Glycine Diluent Product Code: 4AU76 INN or Proposed INN: EPOPROSTENOL Trade Name: FLOLAN TM and Glycine Diluent Product Name: FLOLAN™ and Glycine Diluent Product Code: 4AU76 INN or Proposed INN: EPOPROSTENOL Trade Name: FLOLAN™ and Glycine Diluent Product Name: FLOLAN™ and Glycine Diluent Product Code: 4AU76 I ... | GlaxoSmithKline Research and Development Limited | NULL | Not Recruiting | Female: yes Male: yes | 20 | United States;Canada;Netherlands | |||
| 6 | EUCTR2010-018320-10-IT (EUCTR) | 04/11/201120111104 | 01/03/201220120301 | An extension of study AC-066A301 to investigate safety and tolerabilityof the study medication (epoprostenol for injection) An extension of study AC-066A301 to investigate safety and tolerabilityof the study medication (epop ... | Estensione in aperto dello studio AC-066A301 per valutare la sicurezza e la tollerabilita' dell’ACT-385781A nei pazienti affetti da ipertensione arteriosa polmonare (IAP) - EPITOME-2 Extension Estensione in aperto dello studio AC-066A301 per valutare la sicurezza e la tollerabilita' dell’ACT- ... | Pulmonary Arterial Hypertension MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary Arterial Hypertension MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pu ... | Trade Name: Epoprostenolo per iniezione INN or Proposed INN: EPOPROSTENOL SODIUM Other descriptive name: NA Trade Name: Epoprostenolo per iniezione INN or Proposed INN: EPOPROSTENOL SODIUM Trade Name: Epoprostenolo per iniezione INN or Proposed INN: EPOPROSTENOLSODIUM Other descriptive name ... | Actelion Pharmaceuticals Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 40 | Canada;Spain;Belgium;Netherlands;Italy | |||
| 7 | NCT01462565 (ClinicalTrials.gov) | November 1, 201120111101 | 13/10/201120111013 | Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) Study of a New Thermo Stable Formulation of EpoprostenolSodium to Treat Pulmonary Arterial Hypertens ... | A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN® in Subjects With Pulmonary Arterial Hypertension (PAH). (FLOLAN® is a Registered Trademark of the GlaxoSmithKline Group of Companies.) A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation ... | Hypertension, Pulmonary | Drug: current marketed FLOLAN (epoprostenol sodium);Drug: new thermo stable formulation of epoprostenol sodium Drug: current marketed FLOLAN (epoprostenolsodium);Drug: new thermo stable formulation of epoprosten ... | GlaxoSmithKline | NULL | Completed | 18 Years | 75 Years | All | 16 | Phase 4 | United States;Canada;Netherlands |
| 8 | JPRN-JapicCTI-122017 | 01/8/201120110801 | 03/12/201220121203 | ACT-385781A PAH | Open-label study ACT-385781A in patients with pulmonary arterial hypertension | Pulmonary arterial hypertension (PAH) | Intervention name : ACT-385781A INN of the intervention : epoprostenol Dosage And administration of the intervention : Continuous intravenous infusion Intervention name : ACT-385781A INN of the intervention : epoprostenol Dosage And administration of th ... | Actelion Pharmaceuticals Japan Ltd. | NULL | 20 | BOTH | 10 | Phase 3 | NULL | ||
| 9 | EUCTR2010-018320-10-NL (EUCTR) | 11/07/201120110711 | 12/05/201120110512 | An extension of study AC-066A301 to investigate safety and tolerability of the study medication (epoprostenol for injection) An extension of study AC-066A301 to investigate safety and tolerability of the study medication (epo ... | An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A in patients with pulmonary arterial hypertension (PAH) - EPITOME-2 Extension An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A ... | Pulmonary Arterial Hypertension MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary Arterial Hypertension MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pu ... | Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-385781A INN or Proposed INN: EPOPROSTENOL SODIUM Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-385781A INN or Proposed INN: EPOPROSTENOL SODIUM Trade Name: Epoprostenolfor injection Product Name: Epoprostenolfor injection Product Code: ACT-385781 ... | ACTELION Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | France;Canada;Belgium;Spain;Netherlands;Italy | |||
| 10 | EUCTR2010-018322-40-NL (EUCTR) | 11/07/201120110711 | 19/07/201120110719 | A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension - EPITOME-2 A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ... | A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension - EPITOME-2 A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ... | Pulmonary Arterial Hypertension MedDRA version: 12.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension Pulmonary Arterial Hypertension MedDRA version: 12.1;Level: LLT;Classification code 10064911;Term: P ... | Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-385781A INN or Proposed INN: EPOPROSTENOL SODIUM Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-385781A INN or Proposed INN: EPOPROSTENOL SODIUM Trade Name: Epoprostenolfor injection Product Name: Epoprostenolfor injection Product Code: ACT-385781 ... | ACTELION Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 35 | Phase 3 | Netherlands;Belgium;France;Spain;Italy |